ArticleClinical reviews in allergy & immunology2012
Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis.
Article in Clinical reviews in allergy & immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.Journal of the American Academy of Dermatology · 2017Pooled it
- Tumor necrosis factor inhibitor-related autoimmune disorders in pediatric rheumatology practice: a multicenter nationwide study.Pediatric rheumatology online journal · 2026Article
- Article
- Vasculitis induced by biological agents used in rheumatology practice: A systematic review.Archives of rheumatology · 2022Review
- Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.Arthritis care & research · 2021Article
- Article
- High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.Arthritis & rheumatology (Hoboken, N.J.) · 2018Article
- Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature.Case reports in rheumatology · 2016Article
- [Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Zeitschrift fur Rheumatologie · 2014Article
- The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.Clinics (Sao Paulo, Brazil) · 2013Article
- Less travelled roads in clinical immunology and allergy: drug reactions and the environmental influence.Clinical reviews in allergy & immunology · 2013Review
- Paradoxical inflammation induced by anti-TNF agents in patients with IBD.Nature reviews. Gastroenterology & hepatology · 2012Review
- Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.International journal of inflammation · 2012Article
- Safety of biologic therapy in rheumatoid arthritis.Nature reviews. Rheumatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor necrosis factor alpha (TNFα) inhibitors have been used with good clinical results in the treatment of juvenile idiopathic arthritis (JIA). Anti TNFα therapy is generally well tolerated. Besides the site injection reactions, other various cutaneous manifestations have been encountered as adverse events. Here, we report four young patients receiving treatment with anti-TNFα (infliximab, adalimumab, and etanercept) for JIA developing different skin manifestations more than 1 year after the initiation of therapy. They underwent a dermatological exam. All four patients were ACR-Ped 30 responders to anti-TNF drugs. The first patient developed cutaneous vasculitis, the second one had lichen planus manifestations, while the third and the fourth developed psoriatic palmoplantar pustulosis accompanied by plaque-type psoriasis localized to the scalp. None of the patients had a personal or family history of dermatological diseases. In the first two patients, skin lesions healed with topical treatment after the discontinuation of anti-TNF agent, while psoriatic lesions did not resolve despite discontinuation of the drug and dermatological treatment. TNF inhibition can be both anti-inflammatory and pro-inflammatory. Cutaneous manifestations could be considered as a paradoxical adverse event of the anti-TNF-alpha treatment not only in rheumatoid arthritis but also in juvenile idiopathic arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.